Veranova CEO Mike Riley Recognized in The Medicine Maker’s Power List 2024

Veranova is delighted to announce that its CEO, Mike Riley, has been celebrated in The Medicine Maker’s ‘The Power List 2024’. The list aims to shine a spotlight on the people driving innovation and inspiration in the pharmaceutical industry, enabling the development of world-leading medicines for patients in need. Featuring 30 of the most influential industry players, The Power List 2024 celebrates those leading the way in small molecule, biopharmaceutical, and advanced medicine drug development.

Since assuming the role of Veranova’s CEO in May 2023, Mike Riley has succeeded in positioning the company at the forefront of high-potential areas of development such as personalized and targeted therapies, encompassing ADCs, protein degraders, highly potent APIs and other complex synthetic modalities. Notably, his appointments to the Veranova Scientific Advisory Board include 2022 Nobel Prize Laureate Carolyn Bertozzi.

Mike is a seasoned executive with over 20 years of experience in pharmaceutical contract development and manufacturing operations. In a former role as president of Catalent’s Biotherapeutics business, Riley managed a unit with more than 6,500 employees and revenue exceeding $1 billion.

On his leadership ethos, Mike remarked: “People need to know that you mean what you say, that you will follow through on your commitments, and that you will always seek to make the right ethical decision. Demonstrating that level of integrity in both words and actions sets the right example for your people.”

Read Mike’s full story and learn more about the other inspirational leaders on The Medicine Maker website.

About The Medicine Maker

The Medicine Maker is a leading pharmaceutical industry publication covering the full spectrum of drug development and manufacture across small molecules, biologics, and advanced therapies. Its editors curate content on the most pressing topics, trends, and technologies throughout the pharmaceutical industry for its global digital and print readership. For more information, please visit

Veranova is your next great decision

Discover new ways to advance your science with Veranova.

Contact us